吡拉西坦改善慢性精神分裂症患者认知功能的临床研究

Clinical study of piracetam on cognitive deficits in patients with chronic schizophrenia..

目的 探讨吡拉西坦改善慢性精神分裂症患者认知功能的效果。方法 对68例慢性精神分裂症患者随机分为试验组和治疗组。治疗前进行阳性和阴性症状量表(PANSS)、简明精神状态量表(MMSE)、中国修订韦氏成人智力量表、韦氏记忆量表(WMS)及威斯康星卡片分类测验等评定,然后经利培酮(2.7±0.8)mg/d治疗8周。研究组与利培酮治疗同步使用吡拉西坦1200mg/d治疗,治疗组仅用利培酮治疗。治疗后第8周末再次进行上述评定,将结果与正常人组成的对照组进行比较。结果 治疗前研究组和治疗组的MMSE、WMS及WAIS-RC均低于对照组,差异有非常显著性(P<0.05),提示患者组的认知功能呈广泛性损害;研究组治疗后认知功能评定MMSE、MCST、WMS、WAIS-RC分数与治疗前比较有显著性差异(P<0.05);而治疗组治疗后认知功能测定MCST、WMS、WAIS-RC分数与治疗前比较无差异性(P>0.05)。结论 吡拉西坦对神经细胞有激活、保护和修复作用,能有效改善患者的认知功能,疗效确切。

Objective To study the curative effect of piracetam on cognitive impairment in patients with chronic schizophrenia. Methods Sixty-eight patients with chronic schizophrenia were enrolled in the study. Cognitive function was measured with the Wechsler Memory Scale(WMS) , Mini-Mental State Examination (MMSE) , Wechsler Adult Intelligence Scale,and Wisconsin Card Sorting Test. The patients were assessed with the positive and Negative Syndrome Scale as well. Sixty-eight patients were randomly assigned to study group(n=34) and treatment group(n=34). Both groups were treated with risperidone (2. 7± 0. 8) mg/d,for eight weeks. Patients in study group were treated with piracetam (1200mg/d) simultaneously. Both groups were remeasured after treatment. Results Scores of MMSE, WMS and WAIS-RC of both groups. Before treatment were significantly lower than those of controls(P<0. 05) , which showed cognitive impairments were existing in patients of both groups. The treatment caused a significant changes of MMSE,MCST. WMS and WAIS-RC in study group. While scores of MCST,WMS and WAIS-RC in treatment group did not show any difference after treatment(P>0. 05). Conclusion It was suggested that piracetam has the function of activation, protection and recovery to neurone. Piracetam is effective in the treatment of cognitive impairment.